Systematic Anticoagulation Management

Systematic Anticoagulation Management allows you to make immediate therapy decisions based on current, consistent PT/INR results, for improved patient satisfaction and outcomes.

sam-process
Systematic Anticoagulation Management involves an ongoing process of:

 

PROACTIVE

1. Direct, active patient management for greater engagement in care
Are you engaging in direct and active patient management?

EFFICIENT

2. Patient scheduling and tracking to enhance compliance

Are you using the latest time-saving, web-based technologies for patient scheduling and tracking?

ACCESS

3. Accessible and accurate PT/INR testing to assess time in therapeutic range and mitigate risk of adverse events.
Do you use a PT/INR testing method that supports accessible, accurate and frequent testing?

KNOWLEDGE

4. Patient-specific care, with timely dosage adjustments based on test results
Do you offer patient-specific care and ongoing patient education and staff training?

 

Improved compliance and quality of care

In-office and patient self-testing each improve patient satisfaction, a critical component in determining patient compliance. In fact, 90% of patients preferred in-office testing with a CoaguChek system over lab testing, and 77% preferred self-testing over clinic testing.1,2
What’s more, 87% of patients in a study of home testing were adherent with their prescribed regimen.3

Better adherence in the form of frequent testing and following your recommendations for timely dosage adjustments can lead to increased time in therapeutic range, which in turn improves patient outcomes.4,5

In addition, Systematic Anticoagulation Management helps control costs, by minimizing adverse events5 and improving workflow efficiency to further reduce labor costs.  As illustrated in the graph below and when Systematic Anticoagulation Management is implemented well, as the overall TTR for patients increased to a target range of 70-80%, patients also experienced a consistent and linear decrease in adverse events such as Major Hemorrhage and Thromboembolic events.

Adverse events compared to time in therapeutic range (TTR)5ttr

 

  1. Giles T and Roffidal L. Results of the Prothrombin Office-Testing Benefit Evaluation (PROBE).Cardiovascular Reviews and Reports. 2002;23(1):27-33.
  2. Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol. 2004;128:242-247.
  3. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608-20.
  4. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Meats E and Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367:404-411.
  5. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ: Cardiovasc Qual Outcomes. 2008;1:84-91.